[ad_1] LA JOLLA, Calif., Dec. 5, 2024 /PRNewswire/ — EpicentRx announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the oncolytic adenovirus-delivered transforming growth factor beta (TGFβ) inhibitor, AdAPT-001, […]
